Sign up to save your podcasts
Or
Share ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
View all episodes
By cancerGRACE - H. Jack West, MDDr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
More shows like GRACEcast Radiation Oncology Video
View all
GRACEcast Head and Neck Cancer Audio
2 Listeners
GRACEcast Lung Cancer Video
1 Listeners
GRACEcast Radiation Oncology Audio
0 Listeners
GRACEcast Pancreatic Cancer Audio
0 Listeners
GRACEcast Pancreatic Cancer Video
1 Listeners
GRACEcast Cancer 101 Audio
0 Listeners
GRACEcast Bladder Cancer Video
0 Listeners
GRACEcast Head and Neck Cancer Video NEW
0 Listeners
GRACEcast Cancer 101 Video
0 Listeners